Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06303193
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-08
Brief Title:
Pacritinib a Kinase Inhibitor of CSF1R IRAK1 JAK2 and FLT3 in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or MyelodysplasticMyeloproliferative Neoplasms
Sponsor:
Organization:
National Institutes of Health Clinical Center CC
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
160
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: